Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial-Reference-Cited by-同舟云学术

Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial

Published:2012-05 Issue:5 Volume:23 Page:1348-1353
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Zhang R.X.,Wu X.J.,Wan D.S.,Lu Z.H.,Kong L.H.,Pan Z.Z.,Chen G.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/5/1348/479478/mdr400.pdf

Reference22 articles.

1. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds;Heidelberger;Nature,1957

2. Capecitabine as adjuvant treatment for stage III colon cancer;Twelves;N Engl J Med,2005

3. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome: incidence, recognition and management;Nagore;Am J Clin Dermatol,2000

4. Erythematous eruption of the palms and soles associated with mitotane therapy;Zuehlke;Dermatologica,1974

5. Chemotherapy-induced acral erythema;Baack;J Am Acad Dermatol,1991

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial;Journal of Clinical Oncology;2024-05-20

2. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia;Supportive Care in Cancer;2024-05-14

3. Capecitabine-induced hand foot syndrome: a brief look at possible pathways that may be associated with inflammation;ODÜ Tıp Dergisi;2024-04-30

4. Hand-Foot Syndrome in Cancer Patients on Capecitabine: Examining Prevalence, Impacts, and Associated Risk Factors at a Cancer Centre in Malaysia;2023-12-08

5. The efficacy and adverse events of regorafenib in advanced gastrointestinal stromal tumors after imatinib and sunitinib failure: a systemic review and meta-analysis;2023-01-20